Variability in human skin permeability in vitro: Comparing penetrants with different physicochemical properties

Journal of Pharmaceutical Sciences

Volumn 96, Issue 4, 2007, Pages 824-834

  Akomeah, Franklin K ^a   Martin, Gary P ^a   Brown, Marc B ^a,b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MEDPHARM LTD   (United Kingdom)

^c UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Caffeine; Human epidermis; In vitro; Paraben; Percutaneous absorption; Skin permeability; Variability

Indexed keywords

BUTYL PARABEN; CAFFEINE; METHYL PARABEN;

ARTICLE; CONTROLLED STUDY; DRUG SOLUBILITY; HUMAN; HUMAN TISSUE; HYDROPHILICITY; IN VITRO STUDY; LIPID COMPOSITION; LIPOPHILICITY; PHYSICAL CHEMISTRY; SKIN PERMEABILITY;

EID: 34247495915     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20773     Document Type: Article

References (46)

1. Michaels AS, Chandrasekran SK, Shaw JE. 1975. Drug permeation through human skin: Theory and in vitro experimental measurement. AIChE J 21:985-996.
2. Barry BW. 1983. Dermatological Formulations: Percutaneous Absorption. Drugs and the Pharmaceutical Sciences, Vol 18. New York: Marcel Dekker, pp 95-116.
3. Flynn GL. 1990. Physicochemical determinants of skin absorption. In: Gerrity TR, Henry CJ, editors. Principles of Route-to-Route Extrapolation in Risk Assessment. New York: Elsevier Science Publishing, pp 93-127.
4. Potts RO, Guy RH. 1992. Predicting skin permeability. Pharm Res 9:663-669.
5. Moss GP, Dearden JC, Patel H, Cronin MTD. 2002. Quantitative structure-permeability relationships (QSPRs) for percutaneous absorption. Toxicol In Vitr 16:299-317.
6. Wilschut A, ten Berge WF, Robinson PT, McKone TE. 1995. Estimating skin permeation. The validation of five mathematical skin permeation models. Chemosphere 30:1275-1296.
7. Howes D, Guy RH, Hadgraft J, Heylings J, Hoeck U, Kemper F, Maibach H, Marty JP, Merk H, Parra J, Rekkas D, Rondelli I, Schaefer H, Täuber U, Verbiese N. 1996. Methods for assessing percutaneous absorption, report and recommendations of ECVAM workshop 13. ATLA 24:81-106.
8. Benech-Keiffer F, Wegrich P, Scwarzenbach R, Klećak G, Weber T, Leclaire J, Schaefer H. 2000. Percutaneous absorption of sunscreens in vitro: Interspecies comparison, skin models and reproducibility aspects. Skin Pharmacol Appl Skin Physiol 13:324-335.
9. Chilcott RP, Barai N, Beezer AE, Brain SI, Brown MB, Bunge AL, Burgess S, Cross S, Dalton CH, Dias M, Farinha A, Finnin BC, Gallagher SJ, Green DM, Gunt H, Gwyther RL, Heard CM, Jarvis C, Kamiyama F, Kasting GB, Ley EE, Lim ST, McNaughton G, Morris A, Nazemi M, Pellett MA, Quan YS, Raghavan SL, Roberts M, Romonchuck W, Roper CS, Schenk D, Simonsen L, Simpson A, Traversa BD, Trottet L, Watkinson A, Wilkinson SC, Williams FM, Yamamoto A, Hadgraft J. 2005. Inter-laboratory variation of in vitro diffusion cell measurements: An international multi-centre study using quasi-standardised methods and materials. J Pharm Sci 94:632-638.
10. Southwell S, Barry BW, Woodford R. 1984. Variations in permeability of human skin within and between specimens. Int J Pharm 18:299-309.
11. Rougier A, Lotte C, Maibach HI. 1987. In vivo percutaneous penetration of some organic compounds related to anatomic site in humans: Predictive assessment by the stripping method. J Pharm Sci 76:451-454.
12. Tsai JC, Lin CY, Sheu HM, Lo YL, Huang YH. 2003. Non-invasive characterization of regional variation in drug transport into human stratum corneum in vivo. Pharm Res 20:632-638.
13. Elias PM, Cooper ER, Korc A, Brown BE. 1981. Percutaneous transport in relation to stratum corneum structure and lipid composition. J Invest Dermatol 76:297-301.
14. Cua AB, Wilhelm KP, Maibach HI. 1995. Skin surface lipid and skin friction: Relation to age, sex and anatomical region. Skin Pharmacol 8:246-251.
15. Otberg N, Richter H, Schaefer H, Blume-Peytavi U, Sterry W, Lademann J. 2004. Variations of hair follicle size and distribution in different body sites. J Invest Dermatol 122:14-19.
16. Williams AC, Cornwell PA, Barry BW. 1992. On the non-gaussian distribution of human skin permeabilities. Int J Pharm 86:69-77.
17. Liu P, Nigthingale JAS, Kurihara-Bergstrom T. 1993. Variation of human skin permeation in vitro: Ionic vs. neutral compounds. Int J Pharm 90:171-176.
18. Beck H, Bracher M, Bartnik FG. 1994. Percutaneous absorption of hair dyes: An inter-laboratory comparison of in vivo and in vitro data with rat and pig. In Vitr Toxicol 7:305-312.
19. Heuber F, Ouvrard-Baraton F, Biesse JP, Courtellemont P, Vincent CM, Marty JP. 1998. Pig ear skin as a model for in vitro percutaneous absorption studies: Preliminary results of an inter-laboratory validation. In: Brain RK, Walters KA, editors. Perspectives in Percutaneous Penetration, Vol 6a. Cardiff: STS Publishing, 81 p.
20. Vincent CM, Laugier JP, Aillaud C, Biesse JP, Ouvrard-Baraton F, Courtellemont P, Mikler C, Marty JP. 2000. An example of the relevance of the pig ear skin model: In vitro percutaneous absorption of Ibuprofen in three formulations. In: Brain RK, Walters KA, editors. Perspectives in Percutaneous Penetration, Vol 7a. Cardiff: STS Publishing, 32 p.
21. van de Sandt JJM, van Burgsteden JA, Cage S, Carmichael PL, Dick I, Kenyon S, Korinth G, Larese F, Limasset JC, Maas WJM, Montomoli L, Nielsen JB, Payan JP, Robinson E, Sartorelli P, Schaller KH, Wilkinson SC, Williams FM. 2004. In vitro predictions of the skin absorption of caffeine, testosterone and benzoic acid: A multicentre comparison study. Regul Toxicol Pharmacol 39:271-281.
22. Akomeah F, Nazir T, Martin GP, Brown MB. 2004. Effect of heat on the percutaneous absorption and skin retention of 3 model penetrants. Eur J Pharm Sci 21:337-345.
23. Dias M, Farinha A, Faustino E, Hadgraft J, Pais J, Toscano C. 1999. Topical delivery of caffeine from some commercial formulations. Int J Pharm 182:41-47.
24. Kitagawa S, Li H, Sato S. 1997. Skin permeation of parabens in excised guinea pig dorsal skin, its modification by penetration enhancers and their relationship with n-octanol/water partition coefficients. Chem Pharm Bull 45:1354-1357.
25. Kligman AM, Chrstophers E. 1963. Preparation of isolated sheets of human stratum corneum. Arch Dermatol 88:702-705.
26. Bennet FC, Brown MB, Marriot C, Martin GP. 1996. The diffusion of diclofenac from hyaluronan and other polysaccharide formulations through human skin in vitro. In: Willoughby D, editor. Hyalronan in drug delivery, 4th international workshop, series no 45. pp 86-96.
27. Grams YY, Whitehead L, Cornwell P, Bouwstra J. 2004. On-line visualisation of dye diffusion in fresh unfixed human skin. Pharm Res 21:851-859.
28. Nanayakkara GR, Bartlett A, Forbes b, Marriott C, Whitfield PJ, Brown MB. 2005. The effect of unsaturated fatty acids in benzyl alcohol on the percutaneous permeation of three model penetrants. Int J Pharm 301:129-139.
29. Roskos KV, Maibach H, Guy RH. 1989. The effect of ageing on percutaneous absorption in man. J Pharmacokinet Biopharm 17:617-630.
30. Wesley NO, Maibach H. 2003. Racial (ethnic) differences in skin properties: The objective data. Am J Clin Dermatol 4:843-860.
31. Nielsen JB, Nielsen F. 2000. Dermal in vitro permeation of methiocarb, parclobutrazol and pirimicarb. Occup Environ Med 57:734-737.
32. Bock U, Limberger M, Schmitz S, Haltner E. 2002. ln vitro systems to characterize dermal permeation and penetration. Proceedings of the 4th World meeting on pharmaceutics, biopharmaceutics and pharmaceutical technology, pp 1223-1224.
33. Levin J, Maibach H. 2005. The correlation between transepidermal water loss and percutaneous absorption: An overview. J Control Rel 103:291-299.
34. Illell B, Schaeffer H, Weipierre J, Doucet O. 1991. Follicles play an important role in percutaneous absorption. J Pharm Sci 80:424-427.
35. Treffel P, Muret P, Muret-D'Aniello P, Coumes-Margaret S, Agache P. 1992. Effect of occlusion on in vitro percutaneous absorption of two compounds with different physicochemical properties. Skin Pharmacol 5:108-113.
36. 2 transport through human skin in vitro. Int J Pharm 53:13-24.
37. Sharata H, Burnette RR. 1989. Percutaneous absorption of electron-dense ions across normal and chemically perturbed skin. J Pharm Sci 77: 27-32.
38. Mitragotri S. 2003. Modelling skin permeability to hydrophilic and hydrophobic solutes based on four permeation pathways. J Control Rel 86:69-92.
39. Roberts MS. 1997. Targeted delivery to the skin and deeper tissues: Role of physiology, solute structure and disease. Clin Exp Pharmacol Physiol 24:874-879.
40. Chamin-Remoussenard O, Treffel P, Betchel Y, Agache P. 1993. Surface recovery and stripping methods to quantify percutaneous absorption of caffeine in humans. J Pharm Sci 82:1099-1101.
41. Roberts MS, Cross SE, Anissimov YG. 2004. Factors affecting the formation of a skin reservoir for topically applied solutes. Skin Pharmacol Physiol 17:3-16.
42. Banning TP, Heard CM. 2002. Binding of doxycycline to keratin, melanin and human epidermal tissue. Int J Pharm 235:219-227.
43. Moss GP, Cronin MTP. 2002. Quantitative structure-permeability relationships for percutaneous absorption: Re-analysis of steroid data. Int J Pharm 238:105-109.
44. Barry BW. 2002. Drug delivery routes in skin: A novel approach. Adv Drug Del Rev 54:S31-S40.
45. Roberts MS, Pugh WJ, Hadgraft J. 1996. Epidermal permeability-penetrant structure relationships. 2. The effect of H-bonding groups in penetrants on their diffusion through the stratum corneum. Int J Pharm 132:23-32.
46. Pugh WJ, Degim IT, Hadgraft J. 1996. Epidermal permeability-penetrant structure relationships: 4, QSAR of permeant diffusion across human stratum corneum in terms of molecular weight, H-bonding and electronic charge. Int J Pharm 197:203-211.